PBAC's latest decision on Brolucizumab: Recommended with restriction (2021). Considered for Treatment of subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD) in patients with persistent macular exudation despite at least 6 months of treatment with VEGF inhibitors (aflibercept or ranibizumab).
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
4
first 2019
Submissions
4
2019 → 2021
Eligible population
Patients with subfoveal CNV due to AMD who are non-responsive (persistent macular exudation) despite at least 6 months of treatment with VEGF inhibitors (aflibercept or ranibizumab).
Cost-minimisation analysis; no ICER reported. Prices are commercially sensitive/redacted in the document.
Risk sharing
Risk-sharing arrangement in place — 5% price reduction for brolucizumab acknowledged that there may be uncertain costs in managing brolucizumab-specific safety events in clinical practice, particularly retinal vasculitis (RV) and retinal vascular occlusion (RVO).
Submission history
Nov 2019: Recommended with restriction · Authority Required
Mar 2020: Recommended with restriction · Authority Required
Jul 2020: Not recommended · Restricted
Mar 2021: Recommended with restriction · Authority Required